DelveInsight’s “Diffuse Intrinsic Pontine Glioma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diffuse Intrinsic Pontine Glioma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Diffuse Intrinsic Pontine Glioma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Diffuse Intrinsic Pontine Glioma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Diffuse Intrinsic Pontine Glioma: An Overview
According to the National Cancer Institute (NCI), Diffuse Intrinsic Pontine Glioma (DIPG: also known as Diffuse Midline Glioma (DMG)) are primary central nervous system (CNS) tumors. This means they begin in the brain or spinal cord. It is a rare subtype of glial tumor and is considered a Grade IV tumor.
Diffuse Intrinsic Pontine Glioma (DIPG) harboring the H3 K27M are lethal high-grade pediatric brain tumors that are inoperable and without a cure. DIPGs are all Grade IV tumors, which means they are malignant (cancerous) and fast-growing.
The majority of these tumors are found in the brainstem (which controls many critical functions like breathing, swallowing, and heart rate), but can also be found in other midline structures like the thalamus and spinal cord. It is worth noting that brainstem tumors and tumors of the thalamus as well as the spinal cord were a part of DIPG but now are categorized in the DMG group. DMG primarily affects children, but can occasionally be found in adults as well.
DIPG tumors grow quickly, therefore the symptoms can develop over the course of days or weeks. These can lead to common symptoms such as abnormalities in eye movements, weakness of one side of the face, numbness, difficulty with balance, headaches, nausea, etc.
With advances in DNA sequencing and understanding of tumor genetics, these tumors are increasingly biopsied and analyzed for genetic markers. In fact, DMG is a new classification group recognizing that tumors with these mutations are similar, and thus may respond similarly to certain treatment options.
The first step in treating DIPG is a surgical procedure to make a diagnosis, relieve pressure on the brain, and remove as many tumors as possible safely. DIPG surgery is performed to achieve a “maximum safe resection,” or remove as much of the tumor as possible without causing lasting neurological damage. In most cases, it is not possible to remove the entire tumor, so additional treatment with radiation therapy and/or chemotherapy is necessary.
Diffuse Intrinsic Pontine Glioma Market Key Facts
As per WHO, High-grade glioma (HGG) consists of three types of brain tumor such as Anaplastic Astocytoma (Grade III), Glioblastoma (Grade IV), and Diffuse Intrinsic Pontine Glioma (DIPG) (Grade IV). The total incident population of HGG (comprising DIPG cases as well) in the 7 major markets was 33,788 in 2020.
The incident population of pediatric DIPG and adult DIPG in the United States was 398 cases and 429 cases, respectively, in 2020, which is anticipated to increase in the forecast period 2021-2030. While incident population of DIPG with H3K27 Mutation in the United States was 318 in children and 214 in adults in 2020.
As per a study by Himes et al. titled, “Treatment Strategies in Diffuse Midline Gliomas With the H3K27M Mutation: The Role of Convection-Enhanced Delivery in Overcoming Anatomic Challenges”, primary pediatric brain tumors are rare entities, with an incidence of around 2,200 cases annually. DMG, which makes up approximately 20% of these primary pediatric primary brain tumors, carries among the urgent prognosis.
According to St. Jude Children’s Research Hospital, US, about 10–20% of all childhood brain tumors are DIPG or brainstem gliomas. They are more common in children between the ages of 5 and 10 years but can occur at any age in childhood. Though rarer, they can also occur in adults.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Diffuse Intrinsic Pontine Glioma pipeline therapies. It also thoroughly assesses the Diffuse Intrinsic Pontine Glioma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Diffuse Intrinsic Pontine Glioma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Diffuse Intrinsic Pontine Glioma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Diffuse Intrinsic Pontine Glioma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Diffuse Intrinsic Pontine Glioma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Diffuse Intrinsic Pontine Glioma Epidemiology, Segmented as –
Incident Cases of Diffuse Intrinsic Pontine Glioma (DIPG) in the 7MM
Age-specific Incident Cases of Diffuse Intrinsic Pontine Glioma (DIPG) (Children and Adults) in 7MM
Diagnosed and Treatable Cases of Diffuse Intrinsic Pontine Glioma (DIPG) in the 7MM
Diffuse Intrinsic Pontine Glioma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Diffuse Intrinsic Pontine Glioma market or expected to be launched during the study period. The analysis covers the Diffuse Intrinsic Pontine Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Diffuse Intrinsic Pontine Glioma drugs based on their sale and market share.
The report also covers the Diffuse Intrinsic Pontine Glioma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Diffuse Intrinsic Pontine Glioma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Diffuse Intrinsic Pontine Glioma Market Will Evolve and Grow by 2032 @
Diffuse Intrinsic Pontine Glioma Therapeutics Analysis
Diffuse Intrinsic Pontine Glioma treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.
The most effective and initial treatment for patients with DIPG includes the use of radiation therapy. In cases where surgical resection of a tumor is possible, then surgery is considered as first-line treatment. The goal of surgery is to obtain tissue to determine the tumor type and to remove as much tumor as possible without causing more symptoms for the person.
Several major pharma and biotech companies are developing therapies for Diffuse Intrinsic Pontine Glioma. Currently, Midatech is leading the therapeutics market with its Diffuse Intrinsic Pontine Glioma drug candidates in the most advanced stage of clinical development.
Diffuse Intrinsic Pontine Glioma Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Diffuse Intrinsic Pontine Glioma Therapies Covered in the Report Include:
MTX 110: Midatech
Paxalisib: Kazia Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Diffuse Intrinsic Pontine Glioma Competitive Intelligence Analysis
4. Diffuse Intrinsic Pontine Glioma Market Overview at a Glance
5. Diffuse Intrinsic Pontine Glioma Disease Background and Overview
6. Diffuse Intrinsic Pontine Glioma Patient Journey
7. Diffuse Intrinsic Pontine Glioma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Diffuse Intrinsic Pontine Glioma Treatment Algorithm, Current Treatment, and Medical Practices
9. Diffuse Intrinsic Pontine Glioma Unmet Needs
10. Key Endpoints of Diffuse Intrinsic Pontine Glioma Treatment
11. Diffuse Intrinsic Pontine Glioma Marketed Therapies
12. Diffuse Intrinsic Pontine Glioma Emerging Drugs and Latest Therapeutic Advances
13. Diffuse Intrinsic Pontine Glioma Seven Major Market Analysis
14. Attribute Analysis
15. Diffuse Intrinsic Pontine Glioma Market Outlook (In US, EU5, and Japan)
16. Diffuse Intrinsic Pontine Glioma Companies Active in the Market
17. Diffuse Intrinsic Pontine Glioma Access and Reimbursement Overview
18. KOL Views on the Diffuse Intrinsic Pontine Glioma Market
19. Diffuse Intrinsic Pontine Glioma Market Drivers
20. Diffuse Intrinsic Pontine Glioma Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Carcinoid Tumor Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Carcinoid Tumor Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Carcinoid Tumor Syndrome market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States